IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Plain-language summary

This study collects and examines tissue samples related to IL-2 treatment in patients with advanced melanoma. It included patients with metastatic or unresectable malignant melanoma who were eligible to receive high-dose IL-2. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Beth Israel Deaconess Medical Center

Intervention

IL-2

Start date

2/1/2010

Estimated completion

12/1/2020

Countries

United States

Related genes

Locations

• Boston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Malignant melanoma that is metastatic or unresectable
* Eligible to receive high-dose IL-2
* Tissue block available with adequate tumor to perform RNA extraction and DASL analysis

Exclusion Criteria:

* Prior immunotherapy for unresectable or metastatic disease
* Untreated brain metastases, leptomeningeal disease, or seizure disorder